SenzaGen
Lund
About SenzaGen
Senzagen is a spin out company from Lund University with expertise in immunology, technology and genomics. SenzaGen markets, sells and performs the in vitro GARD sensitization test through its own laboratory and through licenced CROs. It offers animal-free testing of chemical compounds using genomics-based methodology for immunotoxicological assays. Their proprietary lead product family, GARD, potentially replaces the need for animal testing in the cosmetic, chemical and pharmaceutical industries.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.6M
- Last round: Grant (Mar 2017)
- Website: senzagen.com
- Phone: +46 4 62 22 92 56
Industries & Categories
Biotechnology, Chemical, Medical
Social Profiles
Canonical: https://fsome.com/organization/senzagen-136581 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.